Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium–glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020)

2020 ◽  
Author(s):  
Umesh Dashora ◽  
Dipesh C. Patel ◽  
Robert Gregory ◽  
Peter Winocour ◽  
Ketan Dhatariya ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Position Statement ◽  
Joint Position ◽  
Sodium Glucose Cotransporter

scholarly journals Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes

2018 ◽  
Vol 18 (3) ◽  
pp. 117-121 ◽  
Author(s):  
Umesh Dashora ◽  
Dipesh Patel ◽  
Rob Gregory ◽  
Dinesh Nagi
Keyword(s):  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Vascular Disease ◽  
Diabetic Ketoacidosis ◽  
Insulin Treatment ◽  
Position Statement ◽  
Treatment Monitoring ◽  
Peripheral Vascular ◽  
Sodium Glucose Cotransporter

SGLT-2 inhibitors are currently neither licensed nor recommended in people with type 1 diabetes. The management of type 1 diabetes consists essentially of insulin treatment, monitoring and education. SGLT-2 inhibitors can be a useful adjunct to insulin treatment in improving glycaemic control. They may also potentially be helpful in reducing cardiovascular and renal complications in people with type 1 diabetes. However, further studies will be needed to establish this. SGLT-2 inhibitors can cause diabetic ketoacidosis and certain circumstances appear to increase this risk. They should therefore be used with caution all the time and only under specialist supervision. Higher amputation rates have been reported with some SGLT-2 inhibitors and hence they should be used with caution in patients with peripheral vascular disease.

scholarly journals Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)

2019 ◽  
Vol 19 (1) ◽  
pp. 66-72 ◽  
Author(s):  
Umesh Dashora ◽  
Dipesh C Patel ◽  
Robert Gregory ◽  
Peter Winocour ◽  
Ketan Dhatariya ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Ketoacidosis ◽  
Position Statement ◽  
Excessive Alcohol Consumption ◽  
Low Calorie Diet ◽  
Sodium Glucose Cotransporter ◽  
Calorie Diet ◽  
Added Benefit ◽  
Excessive Alcohol

SGLT-2 inhibitors may be increasingly used in people with type 1 diabetes as new licenses are obtained. These drugs have the potential to improve glycaemic control in people with type 1 diabetes with the added benefit of weight loss, better control of blood pressure and more time in optimal glucose range. SGLT-2 inhibitors are associated with higher incidence of diabetic ketoacidosis without significant hyperglycaemia. The present ABCD position statement is to mitigate this risk and other potential complications in people taking these drugs. Particular caution needs to be exercised in people who are at risk of diabetic ketoacidosis due to low calorie diet, illnesses, injuries, starvation, excessive exercise, excessive alcohol consumption and reduced insulin administration among other precipitating factors for diabetic ketoacidosis.

scholarly journals Erratum. Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care 2020;43:90–97

Diabetes Care ◽  
2020 ◽  
Vol 43 (9) ◽  
pp. 2324-2324
Author(s):  
Christian Hampp ◽  
Richard S. Swain ◽  
Casie Horgan ◽  
Elizabeth Dee ◽  
Yandong Qiang ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Ketoacidosis ◽  
Diabetes Care ◽  
Sodium Glucose Cotransporter

scholarly journals Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Diabetes Care ◽  
2015 ◽  
Vol 38 (12) ◽  
pp. 2258-2265 ◽  
Author(s):  
Robert R. Henry ◽  
Payal Thakkar ◽  
Cindy Tong ◽  
David Polidori ◽  
Maria Alba
Keyword(s):  
Type 1 Diabetes ◽  
Efficacy And Safety ◽  
Sodium Glucose Cotransporter

scholarly journals Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Diabetes Care ◽  
2014 ◽  
Vol 37 (5) ◽  
pp. 1480-1483 ◽  
Author(s):  
Bruce A. Perkins ◽  
David Z.I. Cherney ◽  
Helen Partridge ◽  
Nima Soleymanlou ◽  
Holly Tschirhart ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Proof Of Concept ◽  
Open Label ◽  
Sodium Glucose Cotransporter
Sign in / Sign up

Export Citation Format

Share Document